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Tripodal tris(hydroxypyridinone) ligands for
immunoconjugate PET imaging with 89Zr4+:
comparison with desferrioxamine-B†
Michelle T. Ma,*a Levente K. Meszaros,a Brett M. Paterson,b David J. Berry,a
Maggie S. Cooper,a Yongmin Ma,c Robert C. Hiderd and Philip J. Blowera,e
Due to its long half-life (78 h) and decay properties (77% electron capture, 23% β+, Emax = 897 keV, Eav =
397 keV, Eγ = 909 keV, Iγ = 100%) 89Zr is an appealing radionuclide for immunoPET imaging with whole
IgG antibodies. Derivatives of the siderophore desferrioxamine-B (H3DFO) are the most widely used
bifunctional chelators for coordination of 89Zr4+ because the radiolabeling of the resulting immunoconju-
gates is rapid under mild conditions. 89Zr-DFO complexes are reportedly stable in vitro but there is evi-
dence that 89Zr4+ is released in vivo, and subsequently taken up by the skeleton. We have evaluated a
novel tripodal tris(hydroxypyridinone) chelator, H3CP256 and its bifunctional maleimide derivative,
H3YM103, for coordination of Zr
4+ and compared the NMR spectra, and the 89Zr4+ radiolabeling, antibody
conjugation, serum stability and in vivo distribution of radiolabelled immunoconjugates with those of
H3DFO and its analogues. H3CP256 coordinates
89Zr4+ at carrier-free concentrations forming
[89Zr(CP256)]+. Both H3DFO and H3CP256 were eﬃciently radiolabelled using [
89Zr(C2O4)4]
4− at ambient
temperature in quantitative yield at pH 6–7 at millimolar concentrations of chelator. Competition exper-
iments demonstrate that 89Zr4+ dissociates from [89Zr(DFO)]+ in the presence of one equivalent of
H3CP256 (relative to H3DFO) at pH 6–7, resulting largely in [
89Zr(CP256)]+. To assess the stability of
H3DFO and H3YM103 immunoconjugates radiolabelled with
89Zr, maleimide derivatives of the chelators
were conjugated to the monoclonal antibody trastuzumab via reduced cysteine side chains. Both
immunoconjugates were labelled with 89Zr4+ in >98% yield at high speciﬁc activities and the labeled
immunoconjugates were stable in serum with respect to dissociation of the radiometal. In vivo studies in
mice indicate that 89Zr4+ dissociates from YM103-trastuzumab with signiﬁcant amounts of activity
becoming associated with bones and joints (25.88 ± 0.58% ID g−1 7 days post-injection). In contrast, <8%
ID g−1 of 89Zr activity becomes associated with bone in animals administered 89Zr-DFO-trastuzumab over
the course of 7 days. The tris(hydroxypyridinone) chelator, H3CP256, coordinates
89Zr4+ rapidly under
mild conditions, but the 89Zr-labelled immunoconjugate, 89Zr-YM103-trastuzumab was observed to
release appreciable amounts of 89Zr4+ in vivo, demonstrating inferior stability when compared with 89Zr-
DFO-trastuzumab. The signiﬁcantly lower in vivo stability is likely to be a result of lower kinetic stability of
the Zr4+ tris(hydroxypyridinone complex) relative to that of DFO and its derivatives.
Introduction
Antibodies have great utility in the clinic, and can be used
without modification as therapeutics or as conjugates in radio-
therapy or drug delivery. Currently, the FDA has approved
30 monoclonal antibodies for clinical use, with 12 of these
approved for oncological treatments, and hundreds more are
in clinical trials.1 The ability to image antibody biodistribution
and tissue localisation in vivo is useful in patient prognosis
and dosimetry and in guiding selection of therapeutic
regimes and monitoring disease response to antibody-based
therapies, and in stratifying patients for clinical trials. Imaging
†Electronic supplementary information (ESI) available: 1H and 13C NMR data,
reverse phase HPLC and size exclusion HPLC chromatograms, phosphoimages
of ITLC plates, ex vivo biodistribution data. See DOI: 10.1039/c4dt02978j
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antibody distribution in vivo has been mainly achieved with
the use of γ-emitting radionuclides, especially 111In2,3 and
99mTc.4,5 In recent years there has been increased interest in
using positron emission tomography (PET) to study antibody
biodistribution.6 The large molecular weight (∼150 kDa) of
whole antibodies results in slow accumulation in target tissue,
while the lack of domains that mediate clearance and excretion
leads to slow blood clearance. Consequently, extended time
periods (0.5–7 days) are required for the antibody to clear from
non-target tissue and localise at cell receptors in target tissue.
The β+-emitting isotope 89Zr allows these requirements to be
met, possessing suitable decay properties (77% electron
capture, 23% β+, Emax = 897 keV, Eav = 397 keV, Eγ = 909 keV,
Iγ = 100%) and a half-life of 78.5 h.6–9
Zr4+ can accommodate up to eight donors in its coordi-
nation sphere and the high charge of Zr4+ induces a preference
for “hard” Lewis acid donor atoms.8 The acyclic siderophore
ligand desferrioxamine (H3DFO)‡ (Chart 1) contains three
hydroxamate groups. Despite possessing only six donor
ligands, H3DFO eﬃciently complexes radiopharmaceutical
concentrations of 89Zr4+ and has been widely used as a bifunc-
tional chelator for 89Zr. Linking carboxylate, isothiocyanate or
maleimide groups to the terminal amine of H3DFO (e.g.
Chart 1) provides a convenient, stable attachment point for
conjugation to amino acids of antibody side chains.9–14
Density functional theory calculations indicate that the most
energetically favourable coordination geometry of [Zr(DFO)]+
consists of an eight-coordinate complex in which two cis water
molecules and six O atoms of DFO (deprotonated at hydroxa-
mate groups) complex Zr4+.15 A recent report of an octadentate
Zr4+ complex that consists of four bidentate N-methyl aceto-
hydroxamate ligands coordinated to Zr4+ has also provided
insight into Zr4+ hydroxamate structural chemistry and the
stability of such complexes.16
H3DFO-antibody and other H3DFO-protein conjugates
labelled with 89Zr have been successfully employed in imaging
tumours or tumour markers in murine models15,17–23 and
have demonstrated the ability to image known and unknown
tumour lesions in patients in clinical trials.24–26 A very recent
study has described an octadentate chelator containing four
linear hydroxypyridinone groups (each a 1-hydroxy-pyridin-2-
one) that is able to coordinate 89Zr4+ quantitatively.27 The
resulting complex demonstrates comparable stability to that of
[89Zr(DFO)]+, however to the best of our knowledge, a bifunc-
tional derivative of this complex has not been reported, and
the stability of the complex over extended periods of time
in vivo (>24 h) has not been assessed. Another recent report
details the synthesis and 89Zr4+ labelling of a series of octa-
dentate ligands each containing four hydroxamate ligands.28
Linear and macrocyclic derivatives diﬀering in distance
between adjacent hydroxamate groups were prepared, and the
ability of the new chelators to coordinate radiopharmaceutical
concentrations of 89Zr4+ was demonstrably dependent on
the geometry/topology of the ligands. A 36-membered macro-
cyclic tetra(hydroxamate) species was able to coordinate
radiopharmaceutical concentrations of 89Zr in >90% radio-
chemical yield in 30 min, and the resulting complex was more
stable than other homologues when subjected to stability
studies. The only published reports of novel alternative bifunc-
tional chelators for 89Zr describe (i) a linear picolinic acid/
methylenephosphonate “mixed” ligand that has been conju-
gated to trastuzumab,29 and very recently (ii) a linear octaden-
tate tetra(hydroxamate) compound, derived from H3DFO, that
has been attached to a bombesin peptide that targets the
gastrin releasing peptide receptor.30 The former performed
very poorly as a chelator for 89Zr (with low radiochemical yields
of 8–12%). The latter is able to retain 89Zr4+ when challenged
with excess H3DFO over the course of 1 day and appears very
promising, although the stability of the complex to demetalla-
tion has not been assessed beyond the 24 h time point, or
in vivo.
Despite the prevalent use of H3DFO as a ligand to radio-
label antibodies for clinical and preclinical evaluation, some
studies have reported bone uptake suggesting that after pro-
longed exposure to the in vivo milieu, 89Zr dissociates from
DFO and subsequently accumulates in bone,12,15,17 although
this is not consistently reported to be a problematic feature of
H3DFO conjugates.
Hydroxypyridinone ligands and their hexadentate deriva-
tives are extremely eﬀective at sequestering Fe3+, Al3+ and
Ga3+,31–36 and have been studied for their utility for
67Ga3+/68Ga3+ coordination for nuclear medicine appli-
cations.37,38 We previously reported that a tris(hydroxypyridi-
none) ligand, H3CP256
33 and its bifunctional derivative,
H3YM103 (Chart 1), each incorporating three 1,6-dimethyl-
3-hydroxypyridin-4-one groups, have outstanding properties as
Chart 1 Chelators and bifunctional chelators for 89Zr4+ coordination.
‡To avoid confusion over the oxidation state of the metal and the pH being
monitored, we adopt the convention of representing desferrioxamine as
“H3DFO” – neutral and uncharged – even though the primary amine in water is
protonated at pH < 9.
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chelators of the radioisotopes 67Ga3+ and 68Ga3+ at radiophar-
maceutical concentrations.38 The bifunctional chelator
H3YM103, which contains a maleimide group, was originally
developed to allow facile site-specific modification of proteins
through engineered cysteine residues. The tris(hydroxypyridin-
one) ligands are eﬃcient at extremely low concentrations of
chelator, and the resulting complexes and bioconjugates are
stable under in vivo biological conditions. With its six oxygen
donors, we speculated that by analogy to H3DFO, which coordi-
nates to Fe3+, Ga3+ and Zr4+, H3CP256 and H3YM103 might
coordinate to 89Zr4+ under conditions appropriate for con-
venient labelling of proteins, and that the resulting complexes
might be suﬃciently stable for PET imaging with antibodies,
oﬀering an alternative to H3DFO. We note that similar to DFO,
H3CP256 is only capable of providing six oxygen donors, and
cannot coordinatively saturate Zr4+ that can bind up to eight
ligand atoms, however prior to synthesising tetra(hydroxy-
pyridinone) ligands, it was instructive to characterise and
define the behaviour of [89Zr(CP256)]+ and investigate whether
a multidentate ligand based on three 1,6-dimethyl-3-hydroxy-
pyridin-4-one groups can coordinate 89Zr4+.
Herein we describe the 89Zr4+ radiolabelling of H3CP256
and its bifunctional analogue H3YM103 conjugated to the
monoclonal antibody trastuzumab. Trastuzumab is currently
an approved clinical metastatic breast cancer therapeutic. It
binds to the human epidermal growth factor receptor
2 (HER2) and inhibits the over-proliferative eﬀects of HER2
overexpression. Trastuzumab conjugates of H3DFO labelled
with 89Zr have been successfully employed to image HER2
positive tumours and assess HER2 expression levels.24,39,40
Therefore native trastuzumab was utilised here as a model
antibody to assess the properties of a 89Zr-labelled tris-
(hydroxypyridinone) conjugate. The stability and biodistribu-
tion of the immunoconjugate labelled with 89Zr via the novel
tris(hydroxypyridinone) ligand were compared with those of a
trastuzumab immunoconjugate labelled with 89Zr via a H3DFO
ligand. Additionally, we report NMR spectroscopic data for
[Zr(DFO)]+, formed in situ from [Zr(acac)4] and H3DFO. Despite
the widespread use of bifunctional H3DFO ligands for
89Zr lab-
elling, there are no reported spectroscopic data available.
Results
H3CP256 complexation with Zr
4+
When one equivalent of [Zr(acac)4] was added to a solution of
H3CP256 in methanol, a Zr
4+ coordinated complex of CP256
was formed, and the mass spectrum indicated that a mono-
nuclear Zr4+ complex with an m/z value (413.61, z = 2+, 100%
of the normalised spectrum and 826.22, z = 1+, 22.5%) corres-
ponding to [Zr(CP256)]+ ({[Zr(C36H46N7O10)] + H}
2+ calculated =
413.62 m/z, [Zr(C36H46N7O10)]
+ calculated = 826.24) (Fig. 1, top
inset) was present. The mass spectrum did not reveal signifi-
cant populations of any other species (e.g. oligomers or com-
plexes with ligand-to-metal stoichiometric ratios other than
1 : 1) with relative abundance ≥5% (of the normalised
spectrum). In the monocationic complex [Zr(CP256)]+, the
three hydroxyl substituents of the hydroxypyridinone rings are
deprotonated. Under the LCMS conditions employed here, the
complex possessed a retention time of 8.01 min (Fig. 1, top
chromatogram), which is longer than that of H3CP256
(7.47 min), and no other signals in the chromatogram with a
corresponding characteristic natZr mass spectral isotope signa-
ture were detected (with the exception of the signal at 2.78 min
that corresponds to elution of excess natZr4+).
The 1H NMR spectral features of a sample of [Zr(CP256)]+
in methanol-d4 are extremely broad (Fig. 2), presumably a con-
sequence of fluxionality within the complex. Acquiring spectra
at 5 °C resulted in sharpening of some spectral features, but
overall, resonances could not be definitively assigned. Coordi-
nation of Zr4+ resulted in a significant local eﬀect on shifts
and broadening of hydroxypyridinone ring and ring substitu-
ent resonances, but had a less marked eﬀect on resonances of
the tripodal framework –CH2–CH2– protons. Zr
4+ binding to
the aromatic ring resulted in significantly increased shielding
of hydroxypyridinone CH, N–CH3 and CH3 protons, but sub-
stantial deshielding of the hydroxypyridinone CH2 protons.
Aqueous samples acquired in deuterium oxide resulted in 1H
NMR spectra with similar line shapes and chemical shifts
(Fig. S1, ESI†).
In contrast, the 1H NMR spectra of H3DFO and [Zr(DFO)]
+
acquired in methanol-d4 exhibited distinct signals (Fig. 3), and
assignments were made from COSY and HSQC spectra. The 1H
NMR spectrum of H3DFO was consistent with previously
reported data.39 For [Zr(DFO)]+ at low temperatures, reson-
Fig. 1 LCMS of [Zr(CP256)]+. Top: HPLC chromatogram with UV detec-
tion at λ256 of [Zr(CP256)]
+ and corresponding MS signal (inset) of the
fraction eluting at 8.0 min; Bottom: HPLC chromatogram of [89Zr-
(CP256)]+ (8.61 min) (black trace) and [89Zr(ox)4]
4− (blue trace) with
radio-scintillation detection. Diﬀerence in retention times for the same
species between UV and radio-scintillation HPLC chromatograms is a
result of the conﬁguration of the detectors in series.
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ances were broadened compared to those at higher tempera-
tures, and at all temperatures measured, the broadness of
some methylene resonances prohibited observation of coup-
ling constants and splitting patterns. At both 400 and
500 MHz, 1H signals from chemically inequivalent methylene
groups in similar environments are coincident. For both the
free ligand and the Zr4+ coordinated ligand, even though the
two methylene groups both labeled h in Fig. 3 are chemically
distinct, the protons of each group resonate at the same
chemical shift. It is expected that coordination of Zr4+ would
result in formation of enantiomers and other isomers in the
case of either a six, seven or eight coordinate environment.
DFT structures for these alternative environments have pre-
viously been calculated and described.15 Broad line shapes for
[Zr(DFO)]+ obscure separation of resonances of geminal
protons that are necessarily diastereotopic and chemically
inequivalent as a result of the formation of a large chelate ring
upon Zr4+ coordination (with the exception of protons a–e).
Resonances become increasingly broad at lower temperatures.
13C NMR spectra were acquired for both H3DFO and [Zr(DFO)]
+
(Table 1). As was the case with the 1H NMR spectra, 13C reson-
ances are coincident in some instances where two chemically
inequivalent methylene groups are in a similar chemical
environment. Upon Zr4+ coordination, resonances for hydrox-
amate 13CvO groups underwent marked shifts to lower fre-
quencies (Fig. 4). The 1H resonance for methylene group a
moved to higher chemical shift, whilst the corresponding 13C
methylene signal did not shift significantly (40.7 ppm in
H3DFO to 40.6 ppm in [Zr(DFO)]
+). 1H and 13C NMR spectra of
[Zr(DFO)]+ were also recorded in deuterium oxide and similar
spectra were obtained (Fig. S2 and S3, ESI†), thus demonstrat-
ing that the same complex exists in methanol and water.
Under the deuterated solvent conditions employed, any co-
ordinated solvent or water molecules could not be observed,
and there was no evidence to suggest that acetylacetonate
present in solution coordinates to [Zr(DFO)]+.
Fig. 2 1H VT NMR spectra in methanol-d4 of H3CP256 (bottom) and [Zr(CP256)]
+ demonstrating high ﬂuxionality of the complex. Intensity of signal
>5.5 ppm is magniﬁed (×8) relative to region <5.5 ppm. 1H protons of acetylacetonate ligand have exchanged with deuterons.
Fig. 3 Variable temperature 1H NMR spectra in of DFO and [Zr(DFO)]+
in methanol-d4. Additional resonances in [Zr(DFO)]
+ spectra result from
excess [Zr(acac)4], acac, mesylate ion, acetone and solvent. In the case
where chemically inequivalent atoms have the same label, the similar
chemical environment of the atoms resulted in coincident resonances at
500 MHz for 1H NMR, and coincident, or almost coincident resonances
at 100 MHz (on a Bruker Avance 400 spectrometer) for 13C NMR.
Table 1 13C NMR assignments of H3DFO and [Zr(DFO)]
+ in methanol-d4.
For labeling scheme, refer to Fig. 3
Assignment DFO [Zr(DFO)]+
a 40.7 40.6
b, c, d, i, j,
k
24.3, 24.87, 24.90,
27.0, 27.3, 28.0 30.0
23.4, 23.77, 23.85, 27.5, 27.9,
28.31, 28.35, 29.00, 29.09.
e 48.4 51.2
f 28.7, 28.9 26.4
g 31.2, 31.4 32.1, 32.5
h 40.3 39.5, 40.4
l 48.6 51.5
m 20.2 17.0
CvO 173.5, 174.5, 174.7,
174.88, 174.91
164.0, 165.1, 165.5, 174.1,
174.3
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Radiolabelling H3CP256 with
89Zr4+
Addition of [89Zr(ox)4]
4− (0.5 MBq) to a solution of H3CP256
(1 mM, 20 μL) at pH 6.5 resulted in formation of a single radio-
labelled species, [89Zr(CP256)]+, which possessed the same
LCMS retention time as the nonradioactive complex when cor-
rected for delay between detectors (Fig. 1, bottom chromato-
gram – black trace) and demonstrated significantly greater
retention on the C18 reverse-phase column than [89Zr(ox)4]
4−
(Fig. 1, bottom chromatogram – blue trace).
High specific activity is often crucial when synthesising
radiotracers for targeted molecular imaging. High concen-
trations of unlabelled targeting agent lead to receptor “block-
ing” and therefore compromised image interpretation. To
assess the ability of H3CP256 to complex
89Zr4+ at dilute con-
centrations of chelator, 89Zr4+ (∼0.2 MBq, 1 μL) was added to
increasingly dilute solutions of H3CP256 (10 μL, pH 6.5,
100 μM ammonium acetate). Similar experiments were also
undertaken using H3DFO, to compare the relative abilities of
H3DFO and H3CP256 to complex radiochemical concentrations
of 89Zr4+. Aliquots of these reaction solutions were analysed by
ITLC at 10 min, 30 min, 60 min and 120 min reaction time, to
determine the radiochemical yield (Fig. 5). For both chelators,
quantitative coordination of 89Zr4+ was only observed at the
highest and second highest concentrations measured, 10 mM
and 1 mM (>99% radiochemical yield at all time points).
A 10-fold lower concentration of both chelators (100 μM)
resulted in reasonably high radiochemical yields – between 94
and 96% (which would typically be regarded as adequate for
use in imaging without further purification) after 60 min at
ambient temperature. Lower concentrations of H3CP256
(10 μM–100 nM) yielded less than 20% of [89Zr(CP256)]+ at all
time points. Lower concentrations of H3DFO resulted in con-
sistently higher yields compared to H3CP256. For example, for
[H3DFO] = 10 μM at t = 60 min, the radiochemical yield was
90%, and for [H3DFO] = 1 μM, t = 60 min, the radiochemical
yield was 75%.
Competition studies
Competition studies were undertaken, in which increasingly con-
centrated solutions of H3DFO were added to H3CP256 solutions
containing [89Zr(CP256)]+. Solutions of H3CP256 were also added
to H3DFO solutions containing [
89Zr(DFO)]+. The RP-HPLC reten-
tion times of [89Zr(CP256)]+ and [89Zr(DFO)]+ diﬀer under the
conditions employed here, so RP-HPLC was used to distinguish
the products of these reactions (Fig. 6A and B).
Addition of 1 equivalent of H3DFO (10 μL, 1 mM H3DFO,
100 μM ammonium acetate) to a solution containing 1 equi-
valent of H3CP256 (10 μL, 1 mM H3CP256) and [89Zr(CP256)]+
(∼0.4 MBq) did not result in appreciable transmetallation of
89Zr4+ from CP256 to DFO (Fig. 6C). In contrast, addition of 1
equivalent of H3CP256 to 1 equivalent of H3DFO containing
[89Zr(DFO)]+ (∼0.4 MBq) resulted in dissociation of 89Zr4+ from
DFO, and coordination to CP256. There was no discernable
diﬀerence in the ratio of products at 1 h and 12 h, indicating
that equilibrium was reached by 1 h at ambient temperature.
Addition of 10 equivalents of H3DFO (10 μL, 10 mM H3DFO) to
1 equivalent of H3CP256 (10 μL, 1 mM H3CP256) containing
[89Zr(CP256)]+ (∼0.4 MBq) resulted in <15% dissociation of
89Zr4+ from CP256 (>85% remains bound) (Fig. 6C). Addition
of 100 equivalents of H3DFO (10 μL, 100 mM H3DFO) to 1 equi-
valent of H3CP256 (10 μL, 1 mM H3CP256) containing
[89Zr(CP256)]+ (∼0.4 MBq) resulted in ∼65% formation of
[89Zr(DFO)]+ with ∼20% 89Zr4+ remaining bound to CP256
(Fig. 6C). The remaining ∼15% of activity was associated with
a small “shoulder” peak centered at 7.45 min that could not be
resolved from [89Zr(DFO)]+ (8.03 min) and was not present in
either of the chromatograms of [89Zr(DFO)]+ or [89Zr(CP256)]+.
This is presumably an intermediate in the transchelation of
89Zr4+ from CP256 to DFO. Addition of either 10 equivalents or
100 equivalents of H3CP256 to 1 equivalent of H3DFO contain-
Fig. 4 13C NMR spectra in of [Zr(DFO)]+ (top) and DFO (bottom) in
methanol-d4 at 25 °C, demonstrating the shift in
13CvO resonances
upon Zr4+ coordination.
Fig. 5 Radiochemical yield of [89Zr(CP256)]+ (top) and [89Zr(DFO)]+
(bottom) at diﬀerent concentrations of chelator over the course of
two hours. Error bars correspond to one standard deviation.
Paper Dalton Transactions
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ing [89Zr(DFO)]2+ (∼0.4 MBq) resulted in complete transmetal-
lation of 89Zr4+ from DFO to CP256 (Fig. 6D). Both sets of reac-
tions were also duplicated in phosphate buﬀer (pH 7.4, 0.1 M)
for solutions containing competing chelator at 1 mM and
10 mM concentrations, resulting in identical outcomes.
To verify that these reaction products were in fact equili-
brium products (as opposed to kinetic products), 1 equivalent
of H3CP256 (10 μL, 1 mM H3CP256) was added to 10 equi-
valents of H3DFO (10 μL, 10 mM H3DFO) containing
[89Zr(DFO)]2+, and in a separate reaction 1 equivalent of
H3CP256 (10 μL, 1 mM H3CP256) was added to 100 equivalents
of H3DFO (10 μL, 100 mM H3DFO) containing [89Zr(DFO)]2+.
The ratios of products were the same as those previously
observed for the same ratio of chelators (Fig. S4, ESI†). Thus
the order in which the solutions are labelled in these experi-
ments is inconsequential as the reactions are under thermo-
dynamic control.
Lastly, it is conceivable that rapid re-equilibration takes
place on the C18 reverse phase HPLC column under the acidic
mobile phase conditions (0.1% trifluoroacetic acid, pH 1–2).
Attempts to separate reaction products by HPLC at neutral pH
were unsuccessful. Whilst the Rf values of [
89Zr(CP256)]+
(Rf = 0) and [
89Zr(DFO)]+ (Rf = 0–0.5) rendered quantitative
ITLC analysis using the described system impossible (mobile
phase 0.1 M sodium citrate, pH 5.5), the diﬀerences in the
overall appearance of the ITLC plates following visualisation
using a phosphoimager could qualitatively identify which
species predominated in solution. [89Zr(DFO)]+ resulted in
“streaking” whereas [89Zr(CP256)]+ resulted in a single, well-
resolved “spot” (Fig. S5a and S5b, ESI†). To this end, a solution
of [89Zr(DFO)]+ ([H3DFO] = 1 mM, 5 μL) was added to solutions
of H3CP256 (([H3DFO] = 100 μM or 1 mM, 5 μL) to give two
solutions in which the ratio of H3CP256–H3DFO = 0.1 or 1. In
the case of the solution where H3CP256–H3DFO = 1, visualisa-
tion of the ITLC plate revealed that only a single “spot” was
present, indicative of the predominance of [89Zr(CP256)]+ in
solution (Fig. S5c†). In the case of the solution where
H3CP256–H3DFO = 0.1, a single spot with very faint streaking
was observed, again indicating the predominance of
[89Zr(CP256)]+ in solution (Fig. S5d†). This qualitative ITLC evi-
dence corroborated the observation that H3CP256 is able to
successfully compete for 89Zr4+ binding, at concentrations
equal to, or 0.1–0.01 fold lower than that of DFO.
Stability of DFO and CP256 complexes of 89Zr4+ in the
presence of Fe3+
The stabilities of [89Zr(CP256)]+ and [89Zr(DFO)]+ were assessed
in the presence of Fe3+ ions. Solutions of [89Zr(CP256)]+ and
[89Zr(DFO)]+ containing a 10-fold excess of Fe3+ over the
respective chelator were compared by ITLC, to determine the
relative amount of 89Zr4+ that dissociates from the chelator
upon addition of Fe3+ followed by incubation at ambient temp-
erature for 20 min (Fig. 7). In the case of H3DFO, addition of
Fe3+ ([Fe3+] = 1 mM in final solution, [H3DFO] = 100 μM) did
Fig. 6 Reverse phase radiochromatogram of (A) [89Zr(CP256)]+ (black)
and (B) [89Zr(DFO)]+ (dotted line); (C) A solution of [89Zr(CP256)]+ incu-
bated with H3DFO ligand (H3CP256–H3DFO = 1 : 1, black line);
(H3CP256–H3DFO = 1 : 10, blue line); (H3CP256–H3DFO = 1 : 100, red
line); in all experiments, ﬁnal [H3CP256] = 500 μM. (D) A solution of
[89Zr(DFO)]+ incubated with H3CP256 ligand (H3DFO–H3CP256 = 1 : 1,
black line); (H3DFO–H3CP256 = 1 : 10, blue line); (H3DFO–H3CP256 =
1 : 100, red line); in all experiments, ﬁnal [H3DFO] = 500 μM.
Fig. 7 Stability of 89Zr4+ complexes of H3CP256 (left) and H3DFO
(right): ( ) % radiochemical yield of [89Zr(chelator)]+ at 100 μM concen-
tration of chelator; ( ) % intact [89Zr(chelator)]+ as a proportion of total
89Zr4+ (bound + dissociated) after 20 min incubation with 1 mM Fe3+.
Error bars correspond to one standard deviation.
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not result in more than 7% dissociation of 89Zr4+ from DFO,
however, in the case of H3CP256, addition of Fe
3+ ([Fe3+] =
1 mM in final solution, [H3CP256] = 100 μM), resulted in dis-
sociation of almost 86% of 89Zr4+ from the ligand. This was
not observed at measured higher concentrations of H3CP256 –
when [H3CP256] = [Fe
3+] = 1 mM, any measured dissociation of
89Zr4+ from H3CP256 in the timeframe of the experiment
(approximately 3%) was not substantial.
Synthesis and radiolabeling of BFC-trastuzumab immuno-
conjugates
The monoclonal antibody (Mab), trastuzumab, was chosen as
a model antibody for assessing the serum stability and in vivo
stability of 89Zr-coordinated immunoconjugates. Following
reduction of Mab disulfide bonds with tris(2-carboxyethyl)
phosphine (TCEP) to produce free thiol groups, the bifunc-
tional chelators (BFC), H3YM103 and a maleimidopropionate-
desferrioxamine derivative were conjugated to trastuzumab via
the maleimide functional groups. After 30 min reaction time,
the immunoconjugates were separated from unreacted BFC
using a NAP5 Sephadex size exclusion column and analysed
using size exclusion chromatography and ESI-MS. Both the
H3DFO and H3YM103 immunoconjugates possessed the same
retention time as unmodified trastuzumab antibody, demon-
strating that reduction with TCEP and subsequent conjugation
did not result in dissociation or fragmentation of the antibody
in solution.
Following TCEP reduction and conjugation and under the
conditions utilised for ESI-MS analysis the heavy and light
chains of the antibody dissociated in the gas phase, giving rise
to separate signals. In contrast, the ESI mass spectrum of non-
TCEP-treated unmodified trastuzumab antibody revealed that
unmodified/unreduced trastuzumab did not dissociate into
heavy and light chain fragments. To facilitate analysis and
enable comparison between conjugated and unconjugated
trastuzumab antibody fragments, a sample of trastuzumab was
treated with TCEP and separated using a NAP5 Sephadex
cation exchange column. This sample was immediately sub-
jected to ESI-MS analysis. Subsequent deconvolution of the
spectrum revealed the molecular weight of reduced trastuzu-
mab fragments that separated in the gas phase – in this case,
the unconjugated light, heavy and heavy-light chains. The
molecular weight of each observed fragment of reduced trastu-
zumab and the H3DFO and H3YM103 trastuzumab immuno-
conjugates is listed in Table 2.
ESI-MS analysis of trastuzumab immunoconjugates, fol-
lowed by deconvolution of the subsequent spectrum, revealed
that four to eight H3DFO groups were attached to each trastu-
zumab antibody. In the case of a species conjugated to eight
H3DFO groups, three H3DFO chelators were attached to each
heavy chain and one attached to each light chain. There were
no signals corresponding to unconjugated light chain, or a
heavy chain conjugated to less than three H3DFO groups. In
the case of a species conjugated to four H3DFO groups, the
corresponding mass spectral signals indicated that two H3DFO
groups were attached to each associated heavy-light chain frag-
ment. No unconjugated fragments were observed in this spec-
trum. For H3YM103-trastuzumab, the mass spectrum
indicated that a mixture of species was present, varying in the
number of attached H3YM103 groups. From the relative inten-
sities of signals in the ESI mass spectrum, it appeared that
only a small fraction of light chain fragments were conjugated
to a single H3YM103 and the strongest light chain signal corre-
sponded to unconjugated light chain. Signals observed for the
heavy chain corresponded to heavy chain conjugated to zero to
three H3YM103 groups. Signals were also observed for associ-
ated heavy-light chain fragments, conjugated to zero, one and
two H3YM103 groups, all of comparable total ion count
intensity.
It is also noteworthy that each heavy chain signal and each
heavy-light chain signal in the spectra of both immuno-
conjugates and reduced trastuzumab was accompanied by an
additional signal with a diﬀerence of 162–164 Da. This signal
corresponds to one additional hexose unit suggesting the pres-
ence of diﬀerently glycosylated forms of the heavy chain of
trastuzumab in the gas phase.
Size exclusion HPLC measurements were used to determine
the radiochemical yield of 89Zr-labelled immunoconjugates,
and as the radiochemical yield and purity were >98% at the
specific activities listed below, no further purification was
undertaken. Radiolabelled 89Zr-YM103-trastuzumab was
obtained with a radiochemical yield of 98.7% and a specific
activity of 55 MBq mg−1 immunoconjugate. Radiolabelled
89Zr-DFO-trastuzumab was obtained with a radiochemical
yield of 98.3% and a specific activity of 91 MBq mg−1
immunoconjugate.
Antibody-antigen dissociation constants (Kd) for
89Zr-
YM103-trastuzumab and 89Zr-DFO-trastuzumab were deter-
mined in a competitive binding assay using HCC1954 HER2-
Table 2 Summary of immunoconjugate peaks observed by ESI-MS
Assignment m/za
Trastuzumab
Light chain 23 439
Heavy chain 50 594 (50 757)
Light-heavy chain 74 031 (74 194)
H3YM103-trastzumab
Light chain 23 439
Light chain + H3YM103 24 360
Heavy chain 50 594 (50 755)
Heavy chain + H3YM103 51 519 (51 676)
Heavy chain + 2(H3YM103) 52 439 (52 596)
Heavy chain + 3(H3YM103) 53 356 (53 518)
Light-heavy chain 74 031 (74 194)
Light-heavy chain + H3YM103 74 954 (75 118)
Light-heavy chain + 2(H3YM103) 75 877 (76 038)
H3DFO-trastuzumab
Light chain + 1(H3DFO) 24 151
Heavy chain + 3(H3DFO) 52 730 (52 892)
Light-heavy chain + 2(H3DFO) 75 466 (75 617)
a Signal in brackets due to additional hexose unit in variably
glycosylated heavy chain.
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positive cells. For 89Zr-YM103-trastuzumab, Kd = 9.4 nM
(3.28–15.61 nM, 95% confidence interval) and for 89Zr-DFO-
trastuzumab, Kd = 2.6 nM (0.66–4.49 nM, 95% confidence
interval), demonstrating that both labelled immunoconjugates
retain their aﬃnity for the HER2 receptor (Kd = 5 nM).
41
Serum stability studies
To assess the stability of the 89Zr-labelled immunoconjugates
in a biological milieu, 89Zr-DFO-trastuzumab and 89Zr-YM103-
trastuzumab were incubated in fresh serum. The samples were
incubated at 37 °C in a 5% CO2 atmosphere for seven days,
and size exclusion chromatography was used to assess the
stability of the immunoconjugates over this time course. As
the mobile phase (100 mM phosphate buﬀer, pH 7.4) con-
tained EDTA (2 mM), the majority of dissociated 89Zr4+ that is
coordinated to solvent or electrolyte, or weakly bound to
serum proteins, is complexed by EDTA and contributes to a
signal with a retention time of 11–12 min. This was confirmed
experimentally by incubating a solution of serum with [89Zr-
(ox)4]
4− for 48 h – see Fig. S6, ESI.† The chromatogram exhibi-
ted signals at 11.40 min (57% of total radioactivity) with a
shoulder at 11.85 min (30%), and a small signal at 8.80 min
(13%). The former signals correspond to [89Zr(EDTA)] or
small molecular weight 89Zr complexes. The latter signal likely
corresponds to 89Zr bound to a serum protein with molecular
weight <150 kDa (possibly transferrin41) (Fig. S6†). After incu-
bation in serum for 2 days, both 89Zr-DFO-trastuzumab and
89Zr-YM103-trastuzumab were intact, and at 7 days, >95% of
89Zr remained associated with the mAb fraction (Fig. S6†).
Over this time, some aggregation of 89Zr-YM103-trastuzumab
occurred in the serum solution, as evidenced by the appear-
ance of shoulder peaks at lower retention times. In the course
of these studies, it was also observed that neither native
(unmodified) trastuzumab nor reduced trastuzumab (unconju-
gated to chelators) coordinated 89Zr4+.
In vivo PET imaging of [89Zr(CP256)]+ and [89Zr(ox)4]
4−
The in vivo biodistribution and clearance pathway of
[89Zr(CP256)]+ were assessed in C57B1/6j mice (n = 3) and com-
pared to that of [89Zr(ox)4]
4− (n = 1) by PET (Fig. 8). The in vivo
biodistribution of [89Zr(ox)4]
4− was consistent with previous
studies utilising murine models,15,42 and so only a single
animal was utilised in this study. We did not assess the in vivo
biodistribution of [89Zr(DFO)]+ as this has been previously
reported – the complex is excreted via a renal pathway within
20 min PI.15 Initially, [89Zr(ox)4]
4− circulated in the blood pool.
By 15 min post-injection (PI), some 89Zr activity had accumu-
lated at bones and joints (see knee joint in Fig. 8) and this con-
tinued to increase over time. Significant activity was associated
with the blood pool during the first hour PI. By 4 h PI, 89Zr
had significantly accumulated in bones and joints, although
some activity was still observed in the blood pool with the
animal retaining approximately 98% of the original injected
dose (decay corrected, calculated from PET coincidence rates).
In marked contrast, [89Zr(CP256)]+ cleared from the blood pool
rapidly via a renal pathway (Fig. 8 and S7†). For the three
animals used in this study, at 15 min PI, 15–35% of injected
dose was associated with the bladder, and at 60 min PI, the
majority of the injected activity was associated with the
bladder (55–75% of the injected dose, Fig. 8 and S7†),
although the kidneys (1.5–10% injected dose) were also visible
in the whole body scan. This is comparable to what has pre-
viously been reported for [89Zr(DFO)]+.15 After 4 h PI, the frac-
tion of the original injected dose remaining associated with
each animal was 7% for mouse 1, 8% for mouse 2 and 4% for
mouse 3, enabling the kidneys and bladder to be visualised in
all three cases (e.g. Fig. 8).
Biodistribution and PET imaging studies of 89Zr-BFC-
trastuzumab conjugates
The in vivo renal clearance of [89Zr(CP256)]+ was too rapid to
assess its stability in vivo. Furthermore, previous reports docu-
ment similar rapid excretion of the [89Zr(DFO)]+ complex.15
The in vivo biodistributions of 89Zr-YM103-trastuzumab and
89Zr-DFO-trastuzumab were assessed in six weeks-old male
C57Bl/6j mice by ex vivo biodistribution and in vivo PET
imaging studies (n = 3 for each time point). Dissociated 89Zr4+
is thought to accumulate in bone joints and skeleton.12,15,17,43
Fig. 8 Whole body PET images of C57Bl/6j mice administered
10.3 MBq of [89Zr(CP256)]+ (mouse 3, top) and 9.3 MBq of [89Zr(ox)4]
4−
(bottom). [89Zr(CP256)]+ clears rapidly from the blood pool via a renal
pathway. At 10–15 min PI, 35% of injected dose was associated with the
bladder, at 25–30 min PI, 55% of the injected dose was observed in the
bladder and at 1 h PI, 74% activity of the injected does was associated
with the bladder. At 4 h PI, approximately 4% of the original injected
dose remained associated with the animal. In contrast, for the animal
administered [89Zr(ox)4]
4−, 98% of the injected dose remains 4 h PI, and
is associated predominantly with the skeleton. Diﬀerent scaling has
been used for the top three images on the left, because non-bladder
activity was so low that the kidneys could not be visualised without
brightness/contrast enhancement.
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Additionally, mAbs such as trastuzumab typically have long cir-
culation times in the absence of tissues that are positive for
the target receptor (as in this case, in which animals were not
bearing tumours). For the immunoconjugates studied here,
in vivo stability was assessed by quantifying persistence of 89Zr
activity in the blood pool compared to accumulation in bones
and joints.
Ex vivo biodistribution data indicate that after 6 h PI,
activity was associated with the blood pool for both immuno-
conjugates (89Zr-DFO-trastuzumab: 53.4 ± 4.8%ID g−1; 89Zr-
YM103-trastuzumab: 45.4 ± 0.8%ID g−1), along with significant
amounts of activity associated with the spleen, liver, kidneys,
lungs and heart (Fig. 9). Bone uptake was moderate (89Zr-DFO-
trastuzumab: 7.7 ± 0.7%ID g−1; 89Zr-YM103-trastuzumab: 8.3 ±
0.1%ID g−1). The biodistribution profiles of the two immuno-
conjugates were not significantly diﬀerent at 6 h PI. At 1 day
PI, significant amounts of activity were still associated with the
blood pool for both 89Zr-DFO-trastuzumab (33.6 ± 2.4%ID g−1)
and 89Zr-YM103-trastuzumab (26.1 ± 2.3%ID g−1). For
89Zr-DFO-trastuzumab, the relative bone-associated activity
had not altered (7.8 ± 0.7%ID g−1), whereas for 89Zr-YM103-
trastuzumab, relative bone-associated activity almost doubled
(15.1 ± 1.6%ID g−1) compared to that observed at the 6 h PI
time point (Fig. 10). Over the course of a week, relative bone-
associated activity for animals injected with 89Zr-DFO-trastuzu-
mab did not increase (5.1 ± 0.2%ID g−1 at 3 days PI, and 6.5 ±
0.4%ID g−1 at 7 days PI) but bone-associated activity for
animals injected with 89Zr-YM103-trastuzumab increased to
29.0 ± 3.3%ID g−1 at 3 days PI, and did not change substan-
tially thereafter (25.9 ± 0.6%ID g−1 at 7 days PI). For 89Zr-DFO-
trastuzumab, blood associated activity decreased to 27.2 ±
1.0%ID g−1 at 3 days PI and slightly further to 24.4 ±
1.3%ID g−1 at 7 days PI. For 89Zr-YM103-trastuzumab, blood
associated activity decreased to 24.1 ± 1.3%ID g−1 at 3 days PI
and then significantly further to 12.9 ± 0.2%ID g−1 at 7 days
PI. At the conclusion of the experiment (7 days), the ratio of
blood/bone activity (as a ratio of %ID g−1 values) was 3.7 for
animals injected with 89Zr-DFO-trastuzumab, whereas for
animals injected with 89Zr-YM103-trastuzumab, the ratio was
0.5. For both immunoconjugates, the high %ID g−1 in lung,
and its clearance, parallels that in the blood pool suggesting
that the lung radioactivity is largely confined to blood and in
this respect is typical of radiolabelled antibodies showing
delayed clearance from blood.
PET scans acquired at 0.5 h, 6 h, 1 day, 3 days and 7 days PI
were consistent with biodistribution data for both 89Zr-labelled
immunoconjugates (Fig. 11). PET images of animals imaged
with 89Zr-labelled immunoconjugates exhibited predominantly
blood pool associated activity at the 6 h PI time point. After
this time point, the blood pool was still clearly visible out to
7 days PI for the animal administered 89Zr-DFO-trastuzumab,
although some bone activity was observed – for example, the
knee joints were visible from 1 day PI onwards. For the animal
administered 89Zr-YM103-trastuzumab, the blood pool was
Fig. 10 Comparison of 89Zr activity associated with blood pool and
bone (%ID g−1) for animals administered 89Zr-YM103-trastuzumab and
89Zr-DFO-trastuzumab, determined by ex vivo biodistributions. At 7 days
PI, bone uptake is higher than blood retention for animals administered
89Zr-YM103-trastuzumab, whereas for animals administered 89Zr-DFO-
trastuzumab, activity in blood is higher than that associated with bone.
Fig. 9 Biodistribution of 89Zr-labeled trastuzumab immunoconjugates
in normal male C57Bl/6j mice at 6 h ( ), 1 day ( ), 3 days ( ), and 7 days
( ) post-injection. Top: Biodistribution for animals administered
89Zr-YM103-trastuzumab; Bottom: Biodistribution for animals adminis-
tered 89Zr-DFO-trastuzumab. Error bars correspond to standard error of
the mean, (n = 3 for each timepoint). Notably, animals administered
89Zr-YM103-trastuzumab demonstrated signiﬁcantly higher bone
uptake and lower blood pool retention compared to animals adminis-
tered 89Zr-DFO-trastuzumab over the course of the experiment. This is
indicative of the lower in vivo stability of the 89Zr-chelate in
89Zr-YM103-trastuzumab compared to 89Zr-DFO-trastuzumab.
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visible by PET at 1 day PI, but from 3 days PI, activity was pre-
dominantly associated with the skeleton. Indeed, from 1 day
PI, the knee joints of this animal were as prominent in the
scan as the blood pool, and at 3 days PI, and even more so at
7 days PI, the vertebrae, skull and major joints of the animal
were clearly distinguishable. The striking diﬀerence observed
in the comparison of the ratios of blood : bone activity concen-
tration (from ex vivo biodistribution data of the two
89Zr-labelled immunoconjugates at 7 days PI) was clearly dis-
cernable when qualitatively comparing the PET images for the
same time point. Overall, the biodistribution and PET scan-
ning data point to significantly lower in vivo stability of
89Zr-YM103-trastuzumab compared to 89Zr-DFO-trastuzumab
with respect to dissociation of the 89Zr4+ metal complex.
Discussion
When a methanolic or aqueous solution containing Zr4+ was
added to a solution of H3CP256, a single signal, with a reten-
tion time of 8.03 min was observed in the UV-Vis chromato-
gram. The mass spectrum indicated that this compound
corresponded to a Zr4+ complex of CP256, with a 1 : 1 stoichio-
metry. The mass spectrum did not reveal significant popu-
lations of dimeric or multimeric complexes, or 2 : 1 or 1 : 2
complexes, etc., with intensities ≥ 5% (of normalised spec-
trum), indicating that the Zr4+ species in solution is mono-
meric with a stoichiometry of 1 : 1.
NMR samples prepared in the same way resulted in
complex spectra with broad 1H NMR line shapes, presumably
arising from fluxionality in the complex. The complexity of the
1H spectrum at 5 °C in the aromatic region and pyridinone
CH3 region suggest that hydroxypyridinone groups are inequi-
valent and that multiple species exist in solution, that possibly
interconvert via transient dissociation and re-coordination of
hydroxypyridinone O ligand atoms. Indeed, comparatively
sharper resonances at 5 °C with chemical shifts similar to that
of the unbound ligand suggest that a population of com-
pounds containing unbound hydroxypyridinone ligand arms
could exist in solution. In light of the LCMS results that point
to the presence of only a mononuclear 1 : 1 complex in solu-
tion, it is supposed that [Zr(CP256)]+ is highly fluxional with
multiple interconverting isomeric species in solution. Dis-
sociation and reassociation of solvent/water molecules to Zr4+
could also contribute to the observed fluxionality of the
complex. The fluxional behaviour observed for [Zr(CP256)]+ on
the 1H NMR timescale is likely indicative of the kinetic
instability of the complex, and thus in the future 1H NMR
spectroscopic studies could be useful for probing kinetic stabi-
lity of diamagnetic complexes prior to in vivo testing.
In contrast, the [Zr(DFO)]+ complex gave rise to a spectrum
with lineshapes that were suﬃciently resolved to allow for
assignment of NMR resonances in methanol-d4. Observed
broadening of resonances in spectra of [Zr(DFO)]+ at low temp-
eratures was attributed to a component of fluxionality within
the complex, where averaging of signals was observed for a
proton that exchanges between diﬀerent chemical environ-
ments. These diﬀerent environments arise as a result of con-
version between two or more thermodynamically and
kinetically accessible species. Geminal protons (with the excep-
tion of protons labelled a–e (Fig. 3) are inequivalent and dia-
stereotopic. It is possible that the fluxionality within the
system is a result of dissociation and reassociation of water
molecules, or conversion between enantiomers where geminal
protons exchange environments. Neither process necessarily
requires dissociation of Zr4+ from hydroxamate O ligands.
Chemical exchange/dynamic processes in the system in deuter-
ium oxide are slower than the corresponding processes in
methanol-d4 at the same temperature (Fig. S2, ESI†), and at
25 °C in D2O, additional resonances are observed. Coalescence
occurs at comparatively higher temperatures in the case of
[Zr(DFO)]+ in deuterium oxide. The increased complexity at
low temperature in deuterium oxide could be a result of separ-
ation of resonances for geminal protons that are involved in
exchange processes.
Previous reports have described the presence of geometric
isomers for octahedral metal complexes of DFO, arising from
cis–trans isomers with respect to the coordinated O.39 These
species result in multiple sets of signals in the 13C NMR spec-
trum in the 13CvO region, and it has been proposed that the
rearrangement process would not necessitate a transition state
involving dissociation of the ligand from the metal. In the case
of Zr4+, which likely accommodates eight ligands,15 there was
no description of this type of geometric isomerism in the DFT
calculations. We only detect a single set of peaks in the 13CvO
region of the 13C NMR spectrum. Indeed, if cis–trans isomers
(arising from a change in coordination geometry of hydrox-
amate O ligands) interconvert in solution, the process cannot
be detected by 13C NMR under the experimental conditions
Fig. 11 PET scans of C57Bl/6j mice administered 5–6 MBq of
89Zr-YM103-trastuzumab (top) and 89Zr-DFO-trastuzumab (bottom).
PET images corroborate ex vivo biodistribution data, with the skeleton of
the animal administered 89Zr-YM103-trastuzumab clearly visible from 3
days PI. This is in marked contrast to the animal administered 89Zr-DFO-
trastuzumab, where the blood pool remains visible out to 7 days PI.
Dalton Transactions Paper
This journal is © The Royal Society of Chemistry 2015 Dalton Trans., 2015, 44, 4884–4900 | 4893
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
7 
O
ct
ob
er
 2
01
4.
 D
ow
nl
oa
de
d 
on
 2
5/
01
/2
01
7 
18
:2
7:
30
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
employed for this study, although mechanisms could be con-
ceived by which such isomerism occurs, and such isomerism
has been observed for an octadentate Zr4+ complex of four
bidentate N-methyl acetohydroxamate ligands.16 Finally, on
the basis of NMR data, primary amine coordination to Zr4+
cannot be ruled out, although in light of previously reported
DFT calculations15 and the small diﬀerences in 13C chemical
shift for methylene group a, this appears unlikely.
Competition studies demonstrated that H3CP256 was able
to coordinate >85% of 89Zr4+ present in solution when H3DFO
was present in a 10-fold excess, indicating that the conditional
stability constant for [Zr(CP256)]+ is approximately two orders
of magnitude greater than that of [Zr(DFO)]+.
When [89Zr(ox)4]
4− (at radiopharmaceutical concentrations)
was reacted with a solution containing low concentrations of
H3CP256 (10 μM or less), the radiochemical yield was less than
40% over the course of a two hour reaction. In contrast, solu-
tions containing H3DFO under the same conditions (10 μM
chelator) resulted in radiochemical yields over 80% at every
time point. Furthermore, at micromolar concentrations (1 μM
chelator), acceptable yields for H3DFO (80–85%) were achieved
after two hours’ reaction time, in contrast to <30% for
H3CP256 under the same conditions. In the context of radio-
synthesis in a clinical radiopharmacy where very high specific
activity may be required, a H3DFO conjugate will be more
useful than the corresponding H3YM103 conjugate, despite
the higher conditional stability constant of the latter complex.
Such results point to complex equilibria and kinetics, and
demonstrate the limitations of in vitro studies in predicting
in vivo behaviour. It is possible that a Zr4+ complex of CP256 is
more thermodynamically stable than that of DFO, but that in
an environment where ligand concentration is low (<100 μM)
and mechanisms exist whereby dissociated Zr4+ is transported
away from H3CP256 (such as some ITLC conditions employed
in the concentration studies, or in vivo), the lability of
[Zr(CP256)]+ results in dissociation and separation of Zr4+ from
CP256.
The stability of [Zr(DFO)]+ and [Zr(CP256)]+ in the presence
of excess Fe3+ indicated that [Zr(DFO)]+ is (kinetically, presum-
ably) stable in the presence of excess Fe3+, but that CP256 par-
tially dissociates from Zr4+ and coordinates to Fe3+. This
behaviour is consistent with the greater lability of [Zr(CP256)]+
compared to [Zr(DFO)]+. The concentration of Fe3+ utilised in
this experiment is not biologically relevant, but does allow for
a qualitative comparison of the kinetic stabilities of [Zr(DFO)]+
and [Zr(CP256)]+. It is seemingly inconsistent that [89Zr(DFO)]+
is stable in the presence of Fe3+ but dissociates in the presence
of 0.1 equivalent of H3CP256 relative to H3DFO. Zr
4+ can
accommodate up to eight ligands in its coordination sphere,
and it is possible that the reaction mechanisms governing the
kinetics of transchelation involve reaction intermediates or
transition states where 89Zr4+ is coordinated to both DFO and
CP256. In the case of the Fe3+ competition studies, the compet-
ing ligand is absent.
Under the same reaction conditions, the conjugation of
H3YM103 to trastuzumab was less eﬃcient than the conju-
gation of a maleimidopropionate-H3DFO derivative to trastuzu-
mab. This reduced reactivity for H3YM103 is possibly a
consequence of the increased steric bulk of the hydroxypyridi-
none rings compared to the linear H3DFO chain, resulting in a
decrease in the number of chelators that can be accommo-
dated at reduced cysteine side chains in close proximity to one
another, or consequently a decrease in the rate of reaction at
these cysteines.
The maximum specific activity obtained for 89Zr-YM103-
trastuzumab was just over half that achieved for 89Zr-DFO-tras-
tuzumab. Lower concentrations of YM103-trastuzumab (0.5
fold lower) resulted in lower radiochemical yields of approxi-
mately 76%. This is not surprising in light of the concen-
tration studies that demonstrated that H3DFO coordinates
89Zr4+ to give high radiochemical yields (>80%) at lower con-
centrations of chelator. It is also consistent with the obser-
vation that there were less H3YM103 chelators present per
molecule of antibody compared to H3DFO. Higher specific
activities could potentially be achieved at the expense of radio-
chemical yield necessitating the inclusion of a purification
step.
Serum stability studies conducted over 7 days indicated that
<5% 89Zr4+ dissociated from YM103-trastuzumab or DFO-
trastuzumab in serum. However, results from the biodistribu-
tion data and PET images indicate that the [89Zr(YM103)]+
group is not suﬃciently stable in vivo, and after one day, sig-
nificant amounts of 89Zr had dissociated from the tris(hydroxy-
pyridinone) chelator and accumulated at the skeleton of the
animal. At 3 days PI, and even more so at 7 days PI, the PET
image resembles that of the animal administered [89Zr(ox)4]
4−
at the 24 h PI time point. For the animals administered
89Zr-DFO-trastuzumab, observed bone uptake was consistent
with previous reports of 89Zr-labelled DFO-protein conjugates.
These reports have attributed this bone uptake to either
release of 89Zr4+ from the chelator, or metabolism of the
labelled immunoconjugate resulting in accumulation of
89Zr-metabolites in the bone marrow.12,15,17 In light of the
biodistribution profile we observe for animals administered
89Zr-YM103-trastuzumab, we favour interpreting this bone
uptake as deposition of released 89Zr4+ in bone mineral, rather
than accumulation of metabolised fragments of 89Zr-DFO-
trastuzumab. Consistent with this are the reports of
significantly lower bone uptake at comparable time points
(3 days and 7 days) for mice administered 111In-labelled
immunoconjugates.3,22,44,45
Geometric rigidity and kinetic inertness of radiolabelled
complexes is demonstrably important for in vivo stability for
other radiometallic imaging agents,7,46,47 and in the case of
89Zr4+, this is also critical. Despite its higher thermodynamic
stability at neutral pH compared to 89Zr-DFO, the lability of the
[Zr(YM103)]+ complex in vivo leads to either competition from
endogenous ligands (either serum proteins43 such as apo- or
holo-transferrin46 or inorganic mineral anions such as phos-
phate in hydroxyapatite42) for 89Zr4+ binding; or competition
from endogenous metal ions, such as Fe3+,31,33 for hydroxy-
pyridinone coordination.
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Concluding remarks
Lability in an octadentate Zr4+ complex of four N-methyl aceto-
hydroxamate (Me-AHA) ligands, [Zr(Me-AHA)4] has been pre-
viously observed and attempts at radiolabelling Me-AHA with
89Zr4+ to give [89Zr(Me-AHA)4] resulted in radiochemical yields
of only 20%, as opposed to H3DFO that gave >99%.
16 These
results indicate that the prearrangement of hydroxamate
groups in a multidentate ligand is important for coordination
of 89Zr4+. It is possible that the topology of the ligand is an
important factor in determining kinetic stability. The linear
arrangement of the three hydroxamate groups in H3DFO might
contribute to the inertness of [Zr(DFO)]+. The tripodal arrange-
ment of hydroxypyridinone groups in H3CP256 and
H3YM103 might not be optimal for high kinetic stability in
[Zr(CP256)]+ and Zr(YM103)]+. It would be instructive to
compare the lability of [89Zr(DFO)]+ with that of 89Zr4+ com-
plexes of existing tripodal tris(hydroxamate) and cryptate tris
(hydroxamate) ligands.48 However, in light of the structure of
[Zr(Me-AHA)4],
16 it is likely that the incorporation of four
rather than three bidentate chelators into a suitable topology
will be required to improve on the Zr-chelating properties of
DFO. Indeed, recently reported stability constant data indi-
cates a preference for 1 : 4 complexes for the Me-AHA
complex.16 We, like others,16,27 predict that replacing a hexa-
dentate ligand with an octadentate ligand containing eight
coordinating O atoms could increase the specific activity, inert-
ness and complex stability of a 89Zr-labeled immunoconjugate,
reducing the bone uptake observed in small animal rodents
that is observed for H3DFO-immunoconjugates.
Determination of stability constants of complexes of hydroxy-
pyridinone ligands and Zr4+ was beyond the scope of this
present work, and so we cannot comment on the quantitative
thermodynamics of hydroxypyridinone ligands vs. hydroxa-
mate ligands. Nevertheless the competition studies suggest
that the conditional stability constant for [Zr(CP256)]+ under
the conditions of our experiments are around two orders of
magnitude higher than [Zr(DFO)]+. Zr4+ can achieve coordi-
nation geometries that accommodate up to eight ligands, and
it is possible the transchelation of 89Zr4+ from DFO to CP256
(and vice versa) involves a ternary intermediate or transition
state where Zr4+ bridges both ligands. Such a mechanism
allows for rapid release of 89Zr4+ from DFO. However, in the
presence of Fe3+ with no competing ligands, [89Zr(DFO)]+ is
stable within the timeframe of the experiment. On the other
hand, the hydroxypyridinone groups of [89/natZr(CP256)]+ are
labile, and NMR evidence indicates that it is likely that popu-
lations exist where hydroxypyridinone groups are not co-
ordinated to Zr4+. This enables eﬀective Fe3+ competition, and
it is likely that in the case of transmetallation of CP256 from
89Zr4+ to Fe3+, reaction intermediates involve a CP256 ligand
that bridges both Zr4+ and Fe3+ metal ions.
Whilst the competition studies demonstrated that thermo-
dynamically, at radiochemical concentrations, 89Zr4+ preferen-
tially coordinates to H3CP256 over H3DFO, the kinetic lability
of the [Zr(YM103)]+/[Zr(CP256)]+ complex is considerably
greater than that of [Zr(DFO)]+, giving rise to both significant
broadening of signal resonances on the NMR timescale and
ultimately, substantially lower in vivo stability. Metal complex
intermediates where a ligand arm has dissociated from Zr4+,
allowing endogenous competing ligands to complex Zr4+
(either serum proteins43 such as apo- or holo-transferrin41 or
inorganic mineral anions such as phosphate in hydroxy-
apatite42), or endogenous metal ions, such as Fe3+,29,31 to coor-
dinate to the dissociated ligand atoms, are likely to play a role
in the in vivo dissociation and transchelation/transmetallation
pathways. Hence, transchelation rates and mechanisms in one
context do not predict those in another – e.g. Zr4+ transchelates
rapidly from DFO to CP256, yet [Zr(DFO)]+ is more inert than
[Zr(CP256)]+ towards competition with Fe3+. While the mecha-
nisms of release or transchelation of Zr by the chelating agents
are complex and not properly understood, it is clear that in
practical terms, bifunctional chelator derivatives of H3DFO are
preferable to bifunctional chelator derivatives of tris(hydroxy-
pyridinone)/H3CP256 for
89Zr PET imaging with immuno-
conjugates where prolonged in vivo stability is required.
Experimental
Materials and instrumentation
Chemicals and reagents were obtained from Sigma-Aldrich
(Dorset, UK) unless otherwise specified. The highest available
purity (lowest metal ion-containing) chemicals were used.
Sterile water for injection, used to prepare buﬀers, was
obtained from Baxter Healthcare (Newbury, UK). G-25 Illustra
NAP-5 size exclusion columns were purchased from Fisher
Scientific Ltd (Leicestershire, UK) and washed with 0.1 M
ammonium acetate solution, pH 6. Trastuzumab (MabThera,
Roche) was obtained as a 10 mg mL−1 solution from the Phar-
macy Department at Guy’s and St. Thomas’ NHS Trust,
London. Fresh female O+ type human serum was obtained
from a healthy volunteer. High-performance liquid chromato-
graphy (HPLC) analysis was carried out using an Agilent 1200
LC system with in-line UV and gamma detection (Flow-Count,
LabLogic). NMR spectra were acquired on a Bruker Avance 400
spectrometer (Bruker UK Limited, Coventry, UK) equipped
with a 5 mm QNP probe at 400.13 MHz for 1H NMR spectra
(using a zg30 pulse program) and 100.6 MHz for 13C NMR
spectra (using a zgpg30 pulse program), or in the case of low
temperature variable temperature experiments, a Bruker
Avance 500 spectrometer with a triple resonance cryoprobe
with z-gradients at 500 MHz for 1H NMR spectra (using a zg30
pulse program), or in the case of high temperature variable
temperature experiments in deuterium oxide, a Bruker Avance
400 spectrometer with a PH BBO probe at 400.13 MHz for 1H
NMR spectra (using a zg30 pulse program). Spectra were refer-
enced to residual solvent signals, or in the case of deuterium
oxide, an acetone reference. Mass spectra were recorded in the
positive ion mode on an Agilent 6520 Q-TOF LC/MS mass
spectrometer coupled to an Agilent 1200 LC system (Agilent,
Palo Alto, CA). Data were acquired and reference mass-
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corrected via a dual-spray electrospray ionisation source, using
the factory-defined calibration procedure. Analytical reverse
phase LCMS and radio-LCMS traces were acquired using an
Eclipse XDB-C18 column (4.6 × 150 mm, 5 μm) with a 0.5 mL
min−1 flow rate and UV spectroscopic detection at either
214 nm, 256 nm or 270 nm. The LCMS was coupled to a
LabLogic Flow-Count detector with a sodium iodide probe
(B-FC-3200) to give a triple-readout chromatogram (UV-vis,
radioactivity and total ion count). Instant thin layer chromato-
graphy strips (ITLC-SG) were obtained from Varian Medical
Systems UK, Ltd. (Crawley, UK), and ITLC strips were visual-
ised using a Perkin Elmer Storage Phosphor System (Cyclone).
Analytical reverse phase HPLC and radio-HPLC traces were
acquired using an Agilent 1200 LC system and an Agilent
Zorbax Eclipse XDB-C18 column (4.6 × 150 mm, 5 μm) with a
1 mL min−1 flow rate and UV spectroscopic detection at either
214 nm, 256 nm or 270 nm. Analytical size exclusion radio-
HPLC traces were acquired using an Agilent 1200 Series HPLC
system and a Phenomenex Biosep 2000 (300 × 7.8 mm) size
exclusion column with ammonium acetate (0.1 M) mobile
phase and, unless otherwise specified, sodium ethylenedia-
mine tetraacetate (2 mM). The radio-HPLC was coupled to a
LabLogic Flow-Count detector with a sodium iodide probe
(B-FC-3200). Aliquots (10–200 μL) of each radiolabelled
sample were injected onto the column, using a flow rate of
1 mL min−1.
Zirconium-89: no-carrier-added zirconium-89 (radionuclidic
purity >99.9%) produced at the BV Cyclotron, Amsterdam, was
purchased from Perkin Elmer. Solutions containing H4[
89Zr-
(ox)4] (ox = oxalate) in aqueous oxalic acid (1 M) were titrated
with sodium carbonate (1 M) until pH 6–7 (measured by pH
strips) was obtained.
Multidentate chelators and bifunctional derivatives: the tris
(hydroxypyridinone) derivatives, H3CP256 and H3YM103, were
prepared according to previously reported procedures.33,38 Des-
ferrioxamine (mesylate salt) was purchased from Sigma-
Aldrich and used as received. Maleimidopropionate-desferriox-
amine was synthesised according to a previously reported
procedure,12 using 3-(maleimido)propionic acid (N-hydroxysuc-
cinimide ester) (purchased from Alfa Aesar, Ward Hill, Massa-
chusetts). ESI-MS: [C32H53N7O11]
+, m/z = 712.39
(experimental), 712.39 (calculated). 1H NMR DMSO-d6 δ 1.21,
m, 6H; 1.36, m, 6H; 1.49, m, 6H; 1.96, s, 3H; 2.26, t, 3J 7.32,
4H; 2.30, t, 3J 7.26, 2H; 2.57, t, 3J 7.13, 4H; 2.98, m, 6H; 3.44
(integration and splitting obscured by HDO/H2O signal), pre-
sumably 6H; 3.59, t, 3J 7.26, 2H; 6.99, s, 2(CH); 7.79, t, 3J 5.07,
2(NH); 7.92, t, 3J 5.49, 1(NH); 9.65, broad s, 2(OH); 9.71, broad
s, 1(OH). 13C NMR DMSO-d6 δ 20.4, 23.6, 26.1, 27.7, 28.7, 28.9,
30.0, 34.2, 34.3, 38.4, 38.5, 46.9, 47.2, 134.6, 169.4, 170.3,
170.9, 171.5, 172.1.
In situ preparation of Zr4+ complexes of H3CP256 and H3DFO
for NMR spectroscopy
[Zr(acac)4] (zirconium acetylacetonate) (1–1.3 equivalents) in
methanol-d4) was added to H3CP256 in methanol-d4. Similarly,
[Zr(DFO)]+ was prepared by addition of [Zr(acac)4] (1–1.3
equivalents) in methanol-d4 to H3DFO in methanol-d4.
Samples were also prepared using deuterium oxide in place of
methanol-d4. Spectroscopic data are included in Fig. 1–3,
Table 1 and ESI.†
Immunoconjugate preparation
A solution of sodium ethylenediaminetetracetate (3 μL,
50 mM, 10 equivalents) was added to a solution of trastuzu-
mab (100 μL, 20 mg mL−1 in 0.9% aqueous NaCl) to chelate
any adventitious metal ions present. A solution of tris(2-carb-
oxyethyl)phosphine hydrochloride (3 μL, 50 mM, 10 equiv-
alents) was added to the solution of trastuzumab and the
mixture heated at 37 °C for 30 min. The BFC derivatives
(20 equivalents) were added to these reaction solutions
(H3YM103 – 0.25 mg in 2.5 μL DMSO; maleimidopropionate-
H3DFO – 0.20 mg in 4 μL DMSO), and the mixtures heated at
37 °C for 30 min. The reaction solutions were each loaded
onto an Illustra NAP-5 size exclusion column that had been
rinsed with aqueous ammonium acetate solution (0.1 M). The
column was eluted with ammonium acetate solution (0.1 M)
and each fraction (0.5 mL) was analysed by size exclusion
HPLC (λ = 280 nm). In both cases, the second fraction con-
tained approximately half of the total amount of immunocon-
jugate and subsequent size exclusion chromatography after
radiolabelling experiments with this fraction demonstrated
that negligible amounts of unreacted bifunctional chelator
were present. In contrast, radiolabelled products in fraction
three included immunoconjugate and low molecular mass
compounds, presumably unreacted bifunctional chelator that
is available to react with [89Zr(ox)4]
4−. Fraction two was used
exclusively for all further experiments that utilised H3DFO-tras-
tuzumab and H3YM103-trastuzumab. Mass spectra were
acquired using a 350 V fragmentor voltage and a 1500 V capil-
lary voltage, and were deconvoluted using Agilent MassHunter
Qualitative Analysis software, using factory settings for decon-
volution with maximum entropy.
Radiolabelling
LCMS studies: a solution containing [89Zr(ox)4]
4− (500 kBq,
2.5 μL) was added to a solution of H3CP256 (20 μL, 1 mM in
0.1 M ammonium acetate solution), and incubated at room
temperature for 10–15 min. After this time, an aliquot was ana-
lysed by LCMS (flow rate: 0.5 mL min−1; gradient mobile
phase: 100%/0% solvent A/B at 0 min to 0%/100% solvent A/B
at 20 min; solvent A: 0.1% formic acid in water; solvent B:
0.1% formic acid in acetonitrile), and the chromatogram com-
pared with that of [natZr(CP256)]+, prepared by addition of
[Zr(acac)4] (1–2 equiv.) to a solution of H3CP256 (20 μL, 1 mM).
LCMS [natZr(CP256)]+: retention time: 8.00 min;
[Zr(C36H46N7O10)]
+: found 413.61 ((M + H)2+) and 826.22, (M+),
calculated 413.62 and 826.24, respectively; LCMS
[89Zr(CP256)]+: UV-Vis chromatogram, λ254 retention time:
8.01 min, radiochromatogram retention time: 8.61 min. LCMS
[89Zr(ox)]4−: retention time: 3.13 min. Diﬀerence in retention
times for the same species between UV and radio-scintillation
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HPLC chromatograms is a result of the configuration of the
detectors in series.
Concentration dependence of labelling eﬃciency: a solu-
tion containing [89Zr(ox)4]
4− (200 kBq, 10 μL, adjusted to pH
6–7 with sodium carbonate as described above) was added to
solutions of H3CP256 (each 10 μL, [H3CP256] = 10 mM, 1 mM,
100 μM, 10 μM, 1 μM and 100 nM in 0.1 M ammonium acetate
solution) and the solutions were left to react at ambient temp-
erature. Aliquots were analysed at 10, 30, 60 and 120 min
using ITLC-SG strips using an aqueous citrate buﬀer (0.1 M,
pH 5.5) mobile phase. The experiment was undertaken in
triplicate, and each measurement was acquired in duplicate.
The same reactions were also conducted using H3DFO in place
of H3CP256. Activity was visualised by exposure (1–3 min) to a
Perkin Elmer super resolution Storage Phosphor Screen, which
was then imaged using a Perkin Elmer Cyclone Plus Storage
Phosphor System at an image resolution of 300 dpi. To quan-
tify activity, regions of interest (ROI) were selected and the
gross digital light units (DLU) of each ROI summed. A back-
ground constant (DLU mm−2) was determined from an appro-
priate background area of each image, and subtracted from
each ROI. Radiochemical yield was calculated as a fraction of
the net DLU of the ROI corresponding to either the CP256 or
DFO complex relative to the sum of DLU for all ROI for the
specific ITLC strip. [89Zr(CP256)]+: Rf = 0, [
89Zr(DFO)]+: Rf =
0–0.5, [89Zr(ox)4]
4−: Rf > 0.8.
Competition studies: a solution containing [89Zr(ox)4]
4−
(400 kBq, 2 μL) was added to solutions of H3CP256 (1 mM,
10 μL in 0.1 M ammonium acetate) and left to react for
10 min. After this time, aliquots containing H3DFO (1 mM,
10 mM or 100 mM, each 10 μL in 0.1 M ammonium acetate)
were added. Each reaction was analysed using reverse phase
C18 HPLC at 1 h and 12 h (flow rate: 1 mL min−1; gradient
mobile phase: 100%/0% solvent A/B at 0 min to 70%/30%
solvent A/B at 12 min; solvent A: 0.1% trifluoroacetic acid in
water; solvent B: 0.1% trifluoroacetic acid in acetonitrile). In a
similar experiment, [89Zr(ox)4]
4− (400 kBq, 2 μL) was added to
solutions of H3DFO (1 mM, 10 μL in 0.1 M ammonium
acetate) and left to react for 10 min. After this time, aliquots
containing H3CP256 (1 mM, 10 mM or 100 mM, each 10 μL in
0.1 M ammonium acetate) were added, and the reactions were
also analyzed by C18 HPLC at 1 h and 12 h. Additionally, a
solution containing [89Zr(ox)4]
4− (400 kBq, 2 μL) was added to
solutions of H3DFO at higher concentrations (100 mM and
10 mM, both 10 μL in 0.1 M ammonium acetate) and left to
react for 10 min. After this time, aliquots containing H3CP256
(1 mM, 10 μL in 0.1 M ammonium acetate) were added to each
solution and the reactions analysed by C18 HPLC after 1.5 h
reaction time. Retention times for detection with a sodium
iodide radio-HPLC probe: [Zr(CP256)]+: 8.52 min; [Zr(DFO)]+:
8.03 min.
Fe3+ competition studies: a solution containing [89Zr(ox)4]
4−
(250 kBq, 0.5 μL) was added to solutions of H3CP256 (in 0.1 M
ammonium acetate) and left to react for 10 min. After this
time, a solution of FeCl3 (10 mM, 1 μL) was added to each solu-
tion of [89Zr(CP256)]+ (final [Fe3+] = 1 mM; final [H3CP256] =
1 mM or 100 μM; volume = 11 μL in 0.1 M ammonium
acetate). After 20 min, aliquots of each reaction were analysed
by ITLC as described above. Alongside these solutions, separ-
ate reaction solutions that did not contain Fe3+ were also pre-
pared, so as to be able to compare the amount of intact
[89Zr(CP256)]+ in Fe3+ solutions with radiochemical yield in the
absence of Fe3+. The same reactions were also conducted using
H3DFO in place of H3CP256. All reactions were undertaken in
triplicate.
Conjugate labelling: 89Zr-DFO-trastuzumab for PET
imaging: a solution containing [89Zr(ox)4]
4− (12.5 MBq, 21 μL)
was added to a solution containing H3DFO-trastuzumab
(125 μL, 1.1 mg mL−1, 138 μg). After incubation at ambient
temperature for 5–10 min, size exclusion HPLC analysis
demonstrated that the 89Zr-DFO-trastuzumab was present with
radiochemical yield and purity of 98.3% and a specific activity
of 91 MBq mg−1 of immunoconjugate (retention time for
detection with a sodium iodide radio-HPLC probe: 7.12 min).
89Zr-YM103-trastuzumab for PET imaging: a solution contain-
ing [89Zr(ox)4]
4− (12.5 MBq, 21 μL) was added to a solution con-
taining H3YM103-trastuzumab (260 μL, 0.8 mg mL−1, 208 μg).
After incubation at ambient temperature for 5–10 min, size
exclusion HPLC analysis demonstrated that the 89Zr-YM103-
trastuzumab was present with a radiochemical yield of 98.7%
and a specific activity of 55 MBq mg−1 of immunoconjugate
(retention time for detection with a sodium iodide radio-HPLC
probe: 7.12 min). Both solutions of 89Zr-labeled immunoconju-
gate were diluted to 300 μL with 0.1 M ammonium acetate for
duplicate injections.
For dose injections into animals for ex vivo biodistribution
studies, lower amounts of activity but a comparable amount of
antibody were required per animal, relative to dose injections
for animals used for acquisitions of PET images. As a result,
the specific activities of solutions of 89Zr-labelled immuno-
conjugates for ex vivo biodistributions were necessarily lower
than those prepared for PET imaging. 89Zr-DFO-trastuzumab
for ex vivo biodistribution studies: a solution containing
[89Zr(ox)4]
4− (7.4 MBq, 14 μL) was added to a solution contain-
ing H3DFO-trastuzumab (875 μL, 1.2 mg mL−1, 1.05 mg). After
incubation at ambient temperature for 5–10 min, size exclu-
sion HPLC analysis demonstrated that the 89Zr-DFO-trastuzu-
mab was present with a radiochemical yield and purity of
>99% and a specific activity of 7.05 MBq mg−1 of immunocon-
jugate. 89Zr-YM103-trastuzumab for ex vivo biodistribution
studies: a solution containing [89Zr(ox)4]
4− (7.4 MBq, 14 μL)
was added to a solution containing H3YM103-trastuzumab
(600 μL, 1.7 mg mL−1, 1.02 mg). After incubation at ambient
temperature for 5–10 min, size exclusion HPLC analysis
demonstrated that the 89Zr-YM103-trastuzumab was present
with a radiochemical yield and purity of >99% and a specific
activity of 7.3 MBq mg−1 of immunoconjugate. These
89Zr-immunoconjugate solutions were both diluted to 1.3 mL to
provide 12 injections (100 μL each) for biodistribution studies.
Serum stability studies: 89Zr-DFO-trastuzumab and
89Zr-YM103-trastuzumab were radiolabelled as described above
to achieve specific activities of 14 MBq mg−1. An aliquot of
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each immunoconjugate (30 μL, 0.11 mg of immunoconjugate,
1.5 MBq) was incubated with fresh serum (200 μL O+ fresh
human serum from a healthy female volunteer) for 24, 48 or
168 h, after which it was analysed using size exclusion HPLC.
Determination of Kd values for
89Zr-YM103-trastuzumab and
89Zr-DFO-trastuzumab in a competitive binding assay
HCC1954 cells were grown in T175 flasks in culture medium.
Cells were aspirated and washed with phosphate buﬀered
saline (PBS), treated with trypsin to detach the cells from the
flask and washed again with PBS. The cells were resuspended
in Hank’s buﬀered saline solution (HBSS) with 0.2% bovine
serum albumin (BSA), aliquoted to give 2 × 105 cells per tube,
centrifuged at 1000 rpm for 3 min and aspirated. Solutions
containing 89Zr-YM103-trastuzumab (1 nM) and trastuzumab
(1–2000 nM) in HBSS with 0.2% BSA (1 mL) were incubated
with the cells on ice for 1 h in triplicate. The cells were washed
3 times by centrifuging at 1000 rpm for 3 min, aspirating the
supernatant and washing with ice-cold HBSS (1 mL). After
this, radioactivity associated with cell pellets was counted
using a Wallac 1282 Compugamma Universal Gamma
Counter. A one site total binding fit using Prism 5.04 for
Windows was used to fit the curves and determine the dis-
sociation constants. The above procedure was also used to
determine the dissociation constant for 89Zr-DFO-
trastuzumab.
In vivo biodistribution and PET imaging studies
In vivo PET imaging of [89Zr(CP256)]+ and [89Zr(ox)4]
4−: six
weeks-old male C57Bl/6j mice (n = 3) were purchased from
Harlan UK and left to acclimatise for five days before use with
ad libitum access to water and diet. PET images were acquired
in a nanoScan® PC in vivo pre-clinical PET/CT imager (Mediso,
Hungary). For PET imaging a mouse was anesthetised by inha-
lation of a 3% isoflurane–oxygen mixture and placed on the
scanner bed; general anaesthesia was maintained with a
1.5–2.5% isoflurane–oxygen mixture. One lateral tail vein was
cannulated with a 27 ga cannula. A PET scan was started
and approximately one min later the mouse was injected
with 10–12 MBq of [89Zr(CP256)]+ ([H3CP256] = 7 mM) in
100–200 µL ammonium acetate solution (0.1 M) via the cannu-
lated vein. The mouse was scanned for a further 60 min and
allowed to recover from anaesthesia. 30 min whole body PET
scans were also acquired at 4 h post-injection (PI) under iso-
flurane anaesthesia. After the final PET scan the mouse was
killed by cervical dislocation. This protocol was also used to
image the tissue distribution of [89Zr(ox)4]
4−; one mouse was
injected with 9.3 MBq of [89Zr(ox)4]
4− in 200 µL ammonium
acetate solution (0.1 M) via a cannulated tail vein and imaged
as described above.
In vivo biodistribution and PET imaging of 89Zr-immuno-
conjugates: six weeks-old male C57Bl/6j mice were purchased
from Harlan UK and left to acclimatise for five days before use
with ad libitum access to water and diet. Twelve mice were
injected intravenously (tail vein) with 500 kBq (80 μg) of
89Zr-DFO-trastuzumab and twelve with 500 kBq (130 μg) of
89Zr-YM103-trastuzumab. The biodistribution of the radio-
labelled antibody conjugates was assessed at 6 h, 1 day, 3 days
and 7 days PI (n = 3 per time point) as follows. At each time
point mice were culled by CO2 asphyxiation. Blood samples
(0.3–0.8 mL) were collected by cardiac puncture. Mice were dis-
sected and the major thoraco-abdominal organs, salivary
glands, thigh muscle and femora collected for ex vivo tissue
counting. Tissue samples were washed in saline to remove
excess blood then dried on highly absorbent tissue paper and
placed in scintillation vials. Samples were weighed and activi-
ties measured in a Wallac 1282 Compugamma Universal
Gamma Counter. Radiotracer accumulation in each tissue was
calculated as the percentage of injected dose and normalised
for the weight of the sample (%ID g−1). For imaging studies
two mice were injected intravenously with 5–6 MBq (60–70 μg)
of 89Zr-DFO-trastuzumab and two mice were injected with 5–6
MBq (120–130 μg) of 89Zr-YM103-trastuzumab. Whole-body
PET scans were acquired in a nanoPET scanner at 0.5 h, 6 h, 1
day, 3 days and 7 days PI. Mice were culled by cervical dislo-
cation at the end of the study.
All studies were approved by the institutional committee
and conducted in strict compliance with Home Oﬃce (UK)
guidelines on animal experimentation and the corresponding
personal and project licenses.
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